Advent-backed Industria Chimica Emiliana, a producer of API, completed the acquisition of New Zealand Pharmaceuticals, a pharmaceutical company, from Archer Capital, an Australian private equity investment firm. Financial terms were not disclosed. “We place great value on our customer relationships, many of which are incredibly long-standing. This partnership will strengthen our ability to support them through the provision of a broader product mix and facilitate the development and production of important new bile-based API drugs,” Agostino Barazza, ICE Chief Executive Officer..